Development and Validation of AAV-Mediated Liver, Liver-VAT, and Liver-Brain SORT and Therapeutic Regulation of FASN in Hepatic De Novo Lipogenesis
Cells · 2025
DOI: 10.3390/cells14050372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ratulananda Bhadury und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immuno-Inflammation Laboratory, National Institute of Immunology (BRIC-NII), Aruna Asaf Ali Marg, New Delhi 110067, India. Hauptthemen laut MEDLINE: Dependovirus, Lipogenesis, Liver, Brain. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SERB CRG grant, ICMR grant, DBT Ramalingaswami fellowship.
Abstract (Originalsprache)
Hepatic lipogenesis combined with elevated endoplasmic reticulum (ER) stress is central to non-alcoholic steatohepatitis (NASH). However, the therapeutic targeting of key molecules is considerably less accomplished. Adeno-associated virus (AAV)-mediated gene therapies offer a new solution for various human ailments. Comprehensive bio-functional validation studies are essential to assess the impact of AAVs in the target organ for developing both preclinical and clinical gene therapy programs. Here, we have established a robust and efficient protocol for high-titer AAV production to enable detailed Selective ORgan Targeting (SORT) of AAV1, 5, 7, and 8 in vivo. Our results for in vivo SORT showed single organ (liver) targeting by AAV8, no organ targeting by AAV1, and dual organ transduction (liver-brain and liver-VAT) by AAV5 and AAV7. Using a human dataset and preclinical murine models of NASH, we identified an inverse correlation between ER stress-triggered CRELD2 and the de novo lipogenesis driver FASN. Furthermore, liver-specific silencing of CRELD2 via AAV8-shCreld2 strongly supports the contribution of CRELD2 to de novo lipogenesis through FASN regulation. Thus, our study demonstrates a robust method for producing clinically translatable AAVs that could be readily adapted for liver and/or liver-VAT or liver-brain targeted gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immuno-Inflammation Laboratory, National Institute of Immunology (BRIC-NII), Aruna Asaf Ali Marg, New Delhi 110067, India.
ORCID-Profile: Ratulananda Bhadury, Mohammad Athar, Pooja Mishra, Chayanika Gogoi, Devram S Ghorpade
Förderung
- SERB CRG grant
- ICMR grant
- DBT Ramalingaswami fellowship
- NII core grant
- SERB CRG
- ICMR
- BRIC-NII
Zitieren
APA
Bhadury, R., Athar, M., Mishra, P., Gogoi, C., Sharma, S., & Ghorpade, D. S. (2025). Development and Validation of AAV-Mediated Liver, Liver-VAT, and Liver-Brain SORT and Therapeutic Regulation of FASN in Hepatic De Novo Lipogenesis. Cells. https://doi.org/10.3390/cells14050372
Vancouver
Bhadury R, Athar M, Mishra P, Gogoi C, Sharma S, Ghorpade DS. Development and Validation of AAV-Mediated Liver, Liver-VAT, and Liver-Brain SORT and Therapeutic Regulation of FASN in Hepatic De Novo Lipogenesis. Cells. 2025. doi:10.3390/cells14050372
BibTeX
@article{Bhadury2025,
author = {Bhadury, Ratulananda and Athar, Mohammad and Mishra, Pooja and Gogoi, Chayanika and Sharma, Shubham and Ghorpade, Devram S},
title = {Development and Validation of AAV-Mediated Liver, Liver-VAT, and Liver-Brain SORT and Therapeutic Regulation of FASN in Hepatic De Novo Lipogenesis},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14050372}
}
EUVIMED